Our Technologies

Multi-Chimeric Cell Platfrom

Duchenne Muscular Dystrophy
Sickle Cell Disease
Anti-Aging

RNAi Platform

Huntington’s Diseases

CELL-BASED THERAPY AND GENE THERAPY

Duchenne Muscular Dystrophy

Dystrophin Expressing Chimeric Cells (DEC) based therapy developed by Dystrogen Therapeutics aims to target all patients suffering from Duchenne muscular dystrophy, irrespective of existing genetic mutation.

| READ MORE |

Huntington's Disease

Our RNAi therapies will be universal for all diseases caused by CAG repeats expansions (polyglutamine diseases) including: Huntington’s disease, Spinocerebellar ataxias, Dentatorubral Pallidoluysian...

| READ MORE |

Sickle Cell Disease

Dystrogen Therapeutics has developed new multi-chimeric cells for treating patients with Sickle Cell Diseases. Our multi chimeric cells are created via cell fusion of 3 or more cells of hematopoietic origin from three different donors...

| READ MORE |

US Headquarters:

Dystrogen Therapeutics Corporation
1415 W 37th Street
Chicago, Illinois

EU R&D:
Dystrogen Therapeutics
ul. Kasztelańska 49
Poznań 60-316, PL
NIP: 7792482313

General inquiries:
info@dystrogen.com

Investor Relations Contacts:
investor@dystrogen.com

INFORMATION

About
Executive Team
Our Technologies
Pipeline
Investor Relations
Contact us